(NASDAQ: MBX) Mbx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.95%.
Mbx Biosciences's earnings in 2025 is N/A.On average, 3 Wall Street analysts forecast MBX's earnings for 2025 to be -$76,970,339, with the lowest MBX earnings forecast at -$84,546,068, and the highest MBX earnings forecast at -$66,500,662. On average, 3 Wall Street analysts forecast MBX's earnings for 2026 to be -$78,086,481, with the lowest MBX earnings forecast at -$87,887,809, and the highest MBX earnings forecast at -$71,513,275.
In 2027, MBX is forecast to generate -$83,376,458 in earnings, with the lowest earnings forecast at -$86,216,938 and the highest earnings forecast at -$80,535,977.